<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089895</url>
  </required_header>
  <id_info>
    <org_study_id>P03684</org_study_id>
    <nct_id>NCT00089895</nct_id>
  </id_info>
  <brief_title>EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)</brief_title>
  <official_title>Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if early INTEGRILINÂ® (eptifibatide) therapy in patients
      with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death,
      heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed
      provisional use of eptifibatide).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll patients who experience symptoms of acute coronary syndrome
      (experiencing chest pain at rest with episodes lasting at least 10 minutes) and who are
      planned to undergo invasive surgical procedures after being given study drug for 12 to 96
      hours. There are two different treatment groups in this study; approximately half of the
      patients will go to each group and the likelihood of receiving study drug vs. placebo is
      50/50 (like tossing a coin). Medications that are standard of care will be provided to the
      patients (all patients will be given aspirin and standard hospital doses of one of two other
      blood thinning drugs - unfractionated heparin (UFH) or low-molecular-weight heparin). Which
      one patients receive is at the discretion of the Investigator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2004</start_date>
  <completion_date type="Actual">November 1, 2008</completion_date>
  <primary_completion_date type="Actual">November 1, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.</measure>
    <time_frame>96 hours after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of the Composite of Death/MI.</measure>
    <time_frame>30 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9406</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Eptifibatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide (Integrilin)</intervention_name>
    <description>intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG [coronary artery bypass graft]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.</description>
    <arm_group_label>Eptifibatide</arm_group_label>
    <other_name>Integrilin</other_name>
    <other_name>SCH 060936</other_name>
    <other_name>SCH 60936</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous; delivery to match eptifibatide to maintain blind</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give informed consent and comply with study procedures and
             follow-up through 1 year.

          -  Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hours.

          -  Able to be randomized into the trial within 12 hours of having symptoms of acute
             coronary syndrome.

          -  Experiencing symptoms of cardiac ischemia at rest (angina or anginal equivalent) with
             episode(s) lasting at least 10 minutes and have at least 2 of the following:

               -  60 years of age or more

               -  Electrocardiogram changes (ECG)

               -  Elevated troponin (protein released in the blood stream in people suffering from
                  acute coronary syndrome) or CK-MB levels

          -  Or have all 3 of the following:

               -  Prior history of cardiovascular disease

               -  Elevated troponin or CK-MB levels

               -  50-59 years of age

        Exclusion Criteria:

          -  pregnancy (known or suspected)

          -  renal dialysis within 30 days prior to randomizing in study

          -  other serious illnesses or any condition that the investigator feels would pose a
             significant hazard to the patient if the investigational therapy was to be initiated

          -  Stroke (hemorrhagic stroke at any time or non-hemorrhagic stroke within previous 7
             days), central nervous system damage (such as neoplasm, aneurysm, intracranial
             surgery), bleeding disorders (including gastrointestinal bleeding), or recent major
             surgery or major trauma.

          -  History of certain hematologic problems following treatment with heparin or
             eptifibatide.

          -  Therapy with certain related drugs within a short time before randomization into the
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2004</study_first_submitted>
  <study_first_submitted_qc>August 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2004</study_first_posted>
  <results_first_submitted>November 13, 2009</results_first_submitted>
  <results_first_submitted_qc>November 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2009</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>non-ST-segment elevation</keyword>
  <keyword>eptifibatide</keyword>
  <keyword>Integrilin</keyword>
  <keyword>glycoprotein IIb/IIIa inhibitor (GP IIb/IIIa)</keyword>
  <keyword>percutaneous coronary intervention (PCI)</keyword>
  <keyword>coronary artery bypass graph surgery (CABG)</keyword>
  <keyword>catheterization</keyword>
  <keyword>angina</keyword>
  <keyword>ischemia</keyword>
  <keyword>cardiac ischemia</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Eptifibatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients in both treatment groups who were undergoing PCI could receive unblinded eptifibatide provisionally immediately before or during percutaneous coronary intervention (PCI) at the discretion of the investigator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eptifibatide</title>
          <description>Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4722">Number of Subjects Randomized with Intent to Treat</participants>
                <participants group_id="P2" count="4684">Number of Subjects Randomized with Intent to Treat</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4687">Number of Subjects treated</participants>
                <participants group_id="P2" count="4642">Number of Subjects treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical reason</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bleeding</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion criteria met</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not otherwise specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eptifibatide</title>
          <description>Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4722"/>
            <count group_id="B2" value="4684"/>
            <count group_id="B3" value="9406"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="10.6"/>
                    <measurement group_id="B2" value="66.7" spread="10.7"/>
                    <measurement group_id="B3" value="66.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1513"/>
                    <measurement group_id="B2" value="1462"/>
                    <measurement group_id="B3" value="2975"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3209"/>
                    <measurement group_id="B2" value="3222"/>
                    <measurement group_id="B3" value="6431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.</title>
        <time_frame>96 hours after randomization</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Eptifibatide</title>
            <description>Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.</title>
          <population>Intent to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4722"/>
                <count group_id="O2" value="4684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of the Composite of Death/MI.</title>
        <time_frame>30 days after randomization</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Eptifibatide</title>
            <description>Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of the Composite of Death/MI.</title>
          <population>Intent to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4722"/>
                <count group_id="O2" value="4684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through hospital discharge or 120 hours after randomization, whichever occurred first.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eptifibatide</title>
          <description>Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="4686"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>MIDDLE EAR INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENOCORTICAL INSUFFICIENCY ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OPHTHALMOPLEGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>GASTRIC PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4686"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>HEPATITIS A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4686"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>MEDICATION ERROR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>VASCULAR ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>IGA NEPHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>NEPHRITIS INTERSTITIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY TOXIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>NEPHROSCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4686"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4686"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RENAL INFARCT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PLEURAL FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4686"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4686"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4686"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4643"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

